

This reprint might contain references to “Merck” or “Merck KGaA”, which refer to (1) Merck KGaA, Darmstadt, Germany; (2) an affiliate of Merck KGaA, Darmstadt, Germany; or (3) one of the businesses of Merck KGaA, Darmstadt, Germany, which operate as EMD Serono in the healthcare, MilliporeSigma in the life science and EMD Electronics in the electronics business in the U.S. and Canada.

There are two different, unaffiliated companies that use the name “Merck”. Merck KGaA, Darmstadt, Germany, which is providing this content, uses the firm name “Merck KGaA, Darmstadt, Germany” and the business names EMD Serono in the healthcare, MilliporeSigma in the life science and EMD Electronics in the electronics business in the U.S. and Canada. The other company, Merck & Co., Inc. holds the rights in the trademark “Merck” in the U.S. and Canada. Merck & Co., Inc. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the “Merck” trademark in all other countries of the world.

Clinical and Economic Burden of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Barry Hendin,¹ Richard A. Brook,² Ian A. Beren,³ Nathan Kleinman,³ Cindy Fink,⁴ Amy L. Phillips,⁵ Caroline Lobo⁵

¹University of Arizona, Tucson, AZ, USA; ²Better Health Worldwide, Inc., Newfoundland, NJ, USA; ³Workpartners LLC, Cheyenne, WY, USA; ⁴Care Partner Advisor; ⁵EMD Serono, Rockland, MA, USA

Acknowledgments: Writing and editorial was provided by Erich Junge and Phoebe Sadler of Ashfield MedComms (New York, NY, USA) and was funded by EMD Serono, Rockland, MA, USA (CrossRef Funder ID: 10.13039/100004755). The authors had full control of the poster and provided their final approval of all content.

Disclosures:

BH received funding support from EMD Serono. **RAB** is an employee of Better Health Worldwide, Inc. **IAB** is an employee of Workpartners, LLC. Workpartners, LLC received funding from EMD Serono to conduct the study. **NK** is a consultant for Workpartners, LLC. Workpartners, LLC received funding from EMD Serono to conduct the study. **CF** received personal compensation for consulting from EMD Serono **ALP** and **CL** are employees of EMD Serono, Rockland, MA, USA.

Clinical and Economic Burden of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Barry Hendin,¹ Richard A. Brook,² Ian A. Beren,³ Nathan Kleinman,³ Cindy Fink,⁴ Amy L. Phillips,⁵ Caroline Lobo⁵

¹University of Arizona, Tucson, AZ, USA; ²Better Health Worldwide, Inc., Newfoundland, NJ, USA; ³Workpartners LLC, Cheyenne, WY, USA; ⁴Care Partner Advisor; ⁵EMD Serono, Rockland, MA, USA


GET POSTER PDF
Copies of this poster obtained through QR (Quick Response) code are for personal use only and may not be reproduced without written permission of the authors



CONCLUSIONS



Employee who are care partners with spouses/partners with MS had significant comorbidities and direct and indirect costs that varied with MS severity. This real-world, health claims database study demonstrated the need to better understand the care partner's wellness in the management of a chronic condition like MS.



INTRODUCTION

- MS is a chronic disease requiring long-term care
- It is estimated that 80% of the care for patients with MS is provided by informal unpaid care partners¹
- Although previous studies have evaluated the burden among care partners of patients with MS,¹⁻³ there has been very limited research with objective data on employee care partners of patients with MS
- Furthermore, data on the indirect costs of MS are not commonly available in the US
- Employers, health care providers, and care partners will benefit from an improved understanding of the impact of MS on care partners



OBJECTIVE

To evaluate the 1-year clinical and economic impact on employee care partners of patients with MS by disease severity



METHODS

Study Population

- Employee care partners with spouses/partners with MS from the Workpartners Research Reference Database (RRDb) (1/1/2010–12/31/2019) were eligible if: spouse/partner had ≥3 MS-related (ICD-9-CM/ICD-10-CM:340.xx/G35) inpatient/outpatient/disease-modifying therapy claims within 1-year (latest claim=index date); 6-month pre-/1-year post-index enrollment; and age 18–64. Any employees that had MS were excluded

Analyses

- Patients were categorized as mild/moderate/severe based on post-index symptoms: bladder/bowel, psychiatric, cognitive, and physical function
- Costs were calculated using two-stage logistic and generalized linear model regression
- Chi-square tests evaluated demographic/clinical characteristic and 12-month direct/indirect cost differences between categorical variables, and t-tests evaluated differences in continuous variables
- A P-value of <0.05 was used to determine statistical significance. P-values were not adjusted for multiplicity



RESULTS

- Among 1041 employee care partners, 358 (34.4%) spouses/partners had mild MS, 491 (47.2%) moderate MS, and 192 (18.4%) severe MS (**Table 1**)
- Mean [SE] care partner age was 49.0 [0.5] mild, 50.5 [0.4] moderate, 51.7 [0.6] severe; care partner percentage [SE] female was 24.6% [2.3%] mild, 19.8% [1.8%] moderate, 27.6% [3.2%] severe; and mean [SE] care partner CCI scores 0.28 [0.05] mild, 0.30 [0.04] moderate, 0.27 [0.06] severe (**Table 1**)

Table 1. Baseline demographic and clinical characteristics of patients with MS and employee care partners

	Mild (n=358)		Moderate (n=491)		Severe (n=192)	
	Mean/%	S.E.	Mean/%	S.E.	Mean/%	S.E.
Patients with MS						
Age (years)	47.9*†	0.51	49.7*	0.41	50.7†	0.66
Gender (% female)	76.3%	2.3%	80.2%	1.8%	73.4%	3.2%
CCI score	0.34*†	0.04	0.55*	0.06	0.74†	0.10
Care partners (employees)						
Age (years, at index date)	49.0*†	0.50	50.5*	0.41	51.7†	0.64
Gender (% female)	24.6%	2.3%	19.8%†	1.8%	27.6%*	3.2%
Race						
White	25.7%	2.3%	31.8%	2.1%	24.5%	3.1%
Black	3.1%	0.9%	2.2%	0.7%	2.6%	1.2%
Hispanic	5.6%*	1.2%	2.9%*	0.8%	4.2%	1.4%
Other race	1.7%	0.7%	1.0%	0.5%	0.0%	0.0%
Missing	64.0%	2.5%	62.1%	2.2%	68.8%	3.4%
Region (1st digit of zip code)						
0	9.5%*	1.6%	5.5%*	1.0%	5.7%	1.7%
1	10.6%†	1.6%	9.4%†	1.3%	17.7%†*	2.8%
2	6.7%*	1.3%	11.2%*	1.4%	7.3%	1.9%
3	8.1%	1.4%	10.4%	1.4%	8.9%	2.1%
4	6.7%	1.3%	6.7%	1.1%	8.3%	2.0%
5	9.0%†	1.5%	7.7%	1.2%	4.2%†	1.4%
6	6.4%	1.3%	7.5%	1.2%	9.4%	2.1%
7	14.3%	1.9%	14.7%	1.6%	14.1%	2.5%
8	13.7%	1.8%	14.3%	1.6%	9.9%	2.2%
9	14.8%	1.9%	12.6%	1.5%	14.6%	2.6%
Job-related variables						
Annual salary	\$110,249	\$12,597	\$91,816	\$3457	\$80,735	\$4586
Full-time employment	79.6%	2.1%	82.9%	1.7%	83.9%	2.7%
Exempt	42.2%	2.6%	43.2%	2.2%	41.7%	3.6%
Employee tenure (years)	11.1	0.52	11.4	0.43	11.8	0.73
CCI score	0.28	0.05	0.30	0.04	0.27	0.06


Bolded values indicate statistically significant differences between groups. *p<0.05 mild vs. moderate; †p<0.05 mild vs. severe; ‡p<0.05 moderate vs. severe.



RESULTS

- More care partners of moderate/severe vs. mild patients had hyperlipidemia (32.6%/31.8% vs. 21.2%), hypertension (29.5%/29.7% vs. 19.3%), gastrointestinal disease (20.8%/22.9% vs. 13.1%), depression (9.2%/10.9% vs. 3.9%), and anxiety (10.6%/8.9% vs. 4.2%) (**Figure 1**)


Figure 1. Comorbidities during 1-year follow-up for employee care partners by patients' MS disease severity category



*p<0.05 mild vs. moderate; †p<0.05 mild vs. severe; ‡p<0.05 moderate vs. severe.

- Adjusted mean [SE] medical costs were greater for partners of moderate vs. mild/severe patients (\$5025 [\$390] mild, \$7887 [\$518] moderate, \$5302 [\$561] severe; both p<0.001) (**Figure 2**)
- Pharmacy costs [SE] were lower for partners of mild vs. moderate/severe patients (\$1442 [\$126] mild, \$1984 [\$145] moderate, \$2363 [\$278] severe; both p<0.005) (**Figure 2**)
- Sick leave costs [SE] were greater for partners of mild/severe vs. moderate patients (\$485 [\$76] mild, \$286 [\$45] moderate, \$611 [\$130] severe; both p<0.05) (**Figure 2**)

Figure 2. Direct and indirect costs over 1-year follow-up for employee care partners by disease severity category of spouse/partner with MS



Due to rounding, some totals may not correspond with the sum of the separate costs.




Table 1. Baseline demographic and clinical characteristics of patients with MS and employee care partners

	Mild (n=358)		Moderate (n=491)		Severe (n=192)	
	Mean/%	S.E.	Mean/%	S.E.	Mean/%	S.E.
Patients with MS						
Age (years)	47.9*†	0.51	49.7*	0.41	50.7†	0.66
Gender (% female)	76.3%	2.3%	80.2%	1.8%	73.4%	3.2%
CCI score	0.34*†	0.04	0.55*	0.06	0.74†	0.10
Care partners (employees)						
Age (years, at index date)	49.0*†	0.50	50.5*	0.41	51.7†	0.64
Gender (% female)	24.6%	2.3%	19.8%‡	1.8%	27.6%‡	3.2%
Race						
White	25.7%	2.3%	31.8%	2.1%	24.5%	3.1%
Black	3.1%	0.9%	2.2%	0.7%	2.6%	1.2%
Hispanic	5.6%*	1.2%	2.9%*	0.8%	4.2%	1.4%
Other race	1.7%	0.7%	1.0%	0.5%	0.0%	0.0%
Missing	64.0%	2.5%	62.1%	2.2%	68.8%	3.4%
Region (1st digit of zip code)						
0	9.5%*	1.6%	5.5%*	1.0%	5.7%	1.7%
1	10.6%†	1.6%	9.4%‡	1.3%	17.7%†‡	2.8%
2	6.7%*	1.3%	11.2%*	1.4%	7.3%	1.9%
3	8.1%	1.4%	10.4%	1.4%	8.9%	2.1%
4	6.7%	1.3%	6.7%	1.1%	8.3%	2.0%
5	9.0%†	1.5%	7.7%	1.2%	4.2%†	1.4%
6	6.4%	1.3%	7.5%	1.2%	9.4%	2.1%
7	14.3%	1.9%	14.7%	1.6%	14.1%	2.5%
8	13.7%	1.8%	14.3%	1.6%	9.9%	2.2%
9	14.8%	1.9%	12.6%	1.5%	14.6%	2.6%
Job-related variables						
Annual salary	\$110,249	\$12,597	\$91,816	\$3457	\$80,735	\$4586
Full-time employment	79.6%	2.1%	82.9%	1.7%	83.9%	2.7%
Exempt	42.2%	2.6%	43.2%	2.2%	41.7%	3.6%
Employee tenure (years)	11.1	0.52	11.4	0.43	11.8	0.73
CCI score	0.28	0.05	0.30	0.04	0.27	0.06


Bolded values indicate statistically significant differences between groups. †P<0.05 mild vs. moderate; ‡P<0.05 mild vs. severe; §P<0.05 moderate vs. severe.

Figure 1. Comorbidities during 1-year follow-up for employee care partners by patients' MS disease severity category



*P<0.05 mild vs. moderate; †P<0.05 mild vs. severe; ‡P<0.05 moderate vs. severe.

Figure 2. Direct and indirect costs over 1-year follow-up for employee care partners by disease severity category of spouse/partner with MS



Due to rounding, some totals may not correspond with the sum of the separate costs.

